Story thread · 3 reports / 2 sources

Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

cnbc.com · 16mShare

Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.

First report: Morgan Stanley cuts China property forecasts on deeper price drops — investing.com, 2d